Variable Severity of Cardiovascular Phenotypes in Patients with an Early-onset Form of Marfan Syndrome Harboring FBN1 Mutations in Exons 24-32

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2016 Jan 23

PMID 26796135

Citations 11

Authors

Jun Maeda

Kenjiro Kosaki

Junko Shiono

Kazuki Kouno

Ryo Aeba

Hiroyuki Yamagishi

Affiliations

Soon will be listed here.

Abstract

A subgroup of patients with Marfan syndrome (MFS) who have mutations in exons 24-32 of the FBN1 gene manifests severe atrioventricular valve insufficiency and skeletal problems as early as the neonatal period. These patients usually die in the first 2 years of life, thus a region between exons 24 and 32 of FBN1 is recognized as a critical region for this neonatal form of MFS (nMFS). Here, we report five consecutive patients who manifested a cardiovascular phenotype until infancy with mutations in the critical region for nMFS. Although three of these patients showed severe mitral regurgitation and died before reaching 1 year of age, the remaining two patients survived for over 5 years under medical and/or surgical interventions. Two splicing mutations and one missense mutation were identified in the three deceased patients, whereas two missense mutations were found in the two survivors. Currently, the clinical severity of patients with early-onset MFS harboring mutations in the critical region for nMFS seem to be more variable than ever thought, and intensive treatments are recommended even in this subgroup of patients with MFS.

Citing Articles

Neonatal Marfan syndrome: a case report of a novel fibrillin 1 mutation, with genotype-phenotype correlation and brief review of the literature.

Pugnaloni F, De Rose D, Digilio M, Magliozzi M, Braguglia A, Valfre L Ital J Pediatr. 2024; 50(1):183.

PMID: 39294662 PMC: 11411867. DOI: 10.1186/s13052-024-01756-0.

Causative role of a novel intronic indel variant in FBN1 and maternal germinal mosaicism in Marfan syndrome.

Bai Y, Sun Y, Yu C, Xia Y, Wu J, Wang L Orphanet J Rare Dis. 2024; 19(1):209.

PMID: 38773661 PMC: 11110283. DOI: 10.1186/s13023-024-03139-4.

Genotype-phenotype spectrum and prognosis of early-onset Marfan syndrome.

Kemezyte A, Gegieckiene R, Burnyte B BMC Pediatr. 2023; 23(1):539.

PMID: 37891508 PMC: 10612290. DOI: 10.1186/s12887-023-04357-8.

Marfan Syndrome: Enhanced Diagnostic Tools and Follow-up Management Strategies.

Marelli S, Micaglio E, Taurino J, Salvi P, Rurali E, Perrucci G Diagnostics (Basel). 2023; 13(13).

PMID: 37443678 PMC: 10340634. DOI: 10.3390/diagnostics13132284.

The fibrillinopathies: New insights with focus on the paradigm of opposing phenotypes for both FBN1 and FBN2.

Peeters S, De Kinderen P, Meester J, Verstraeten A, Loeys B Hum Mutat. 2022; 43(7):815-831.

PMID: 35419902 PMC: 9322447. DOI: 10.1002/humu.24383.

References

Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M . Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003; 22(3):199-208. DOI: 10.1002/humu.10249. View

Tiecke F, Katzke S, Booms P, Robinson P, Neumann L, Godfrey M . Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet. 2001; 9(1):13-21. DOI: 10.1038/sj.ejhg.5200582. View

Giusti B, Porciani M, Brunelli T, Evangelisti L, Fedi S, Gensini G . Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J. 2003; 24(22):2038-45. DOI: 10.1016/j.ehj.2003.08.020. View

Wang M, Wang J, Cisler J, Imaizumi K, Burton B, Jones M . Three novel fibrillin mutations in exons 25 and 27: classic versus neonatal Marfan syndrome. Hum Mutat. 1997; 9(4):359-62. DOI: 10.1002/(SICI)1098-1004(1997)9:4<359::AID-HUMU10>3.0.CO;2-1. View

Lacro R, Dietz H, Sleeper L, Yetman A, Bradley T, Colan S . Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014; 371(22):2061-71. PMC: 4386623. DOI: 10.1056/NEJMoa1404731. View

Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G . Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015; 36(32):2160-6. DOI: 10.1093/eurheartj/ehv151. View

Barnett C, Wilson G, Chiasson D, Gross G, Hinek A, Hawkins C . Central nervous system abnormalities in two cases with neonatal Marfan syndrome with novel mutations in the fibrillin-1 gene. Am J Med Genet A. 2010; 152A(9):2409-12. DOI: 10.1002/ajmg.a.33406. View

Booms P, Cisler J, Mathews K, Godfrey M, Tiecke F, Kaufmann U . Novel exon skipping mutation in the fibrillin-1 gene: two 'hot spots' for the neonatal Marfan syndrome. Clin Genet. 1999; 55(2):110-7. DOI: 10.1034/j.1399-0004.1999.550207.x. View

Pettersen M, Du W, Skeens M, Humes R . Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr. 2008; 21(8):922-34. DOI: 10.1016/j.echo.2008.02.006. View

10.

Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U . Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet. 1999; 65(4):1007-20. PMC: 1288233. DOI: 10.1086/302582. View

11.

Loeys B, Dietz H, Braverman A, Callewaert B, De Backer J, Devereux R . The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47(7):476-85. DOI: 10.1136/jmg.2009.072785. View

12.

Hennekam R . Severe infantile Marfan syndrome versus neonatal Marfan syndrome. Am J Med Genet A. 2005; 139(1):1. DOI: 10.1002/ajmg.a.30979. View

13.

Ades L, Haan E, Colley A, Richard R . Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan syndrome. J Med Genet. 1996; 33(8):665-71. PMC: 1050701. DOI: 10.1136/jmg.33.8.665. View

14.

Stheneur C, Faivre L, Collod-Beroud G, Gautier E, Binquet C, Bonithon-Kopp C . Prognosis factors in probands with an FBN1 mutation diagnosed before the age of 1 year. Pediatr Res. 2010; 69(3):265-70. DOI: 10.1203/PDR.0b013e3182097219. View

15.

Loeys B, Nuytinck L, Delvaux I, de Bie S, De Paepe A . Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med. 2001; 161(20):2447-54. DOI: 10.1001/archinte.161.20.2447. View

16.

Grewal N, Franken R, Mulder B, Goumans M, Lindeman J, Jongbloed M . Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: relevance for therapy?. Heart Vessels. 2015; 31(5):795-806. PMC: 4850207. DOI: 10.1007/s00380-015-0703-z. View

17.

Faivre L, Collod-Beroud G, Callewaert B, Child A, Binquet C, Gautier E . Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation. Eur J Hum Genet. 2008; 17(4):491-501. PMC: 2734964. DOI: 10.1038/ejhg.2008.207. View

18.

Groenink M, den Hartog A, Franken R, Radonic T, de Waard V, Timmermans J . Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013; 34(45):3491-500. DOI: 10.1093/eurheartj/eht334. View

19.

Tynan K, Comeau K, Pearson M, Wilgenbus P, Levitt D, Gasner C . Mutation screening of complete fibrillin-1 coding sequence: report of five new mutations, including two in 8-cysteine domains. Hum Mol Genet. 1993; 2(11):1813-21. DOI: 10.1093/hmg/2.11.1813. View

20.

Pepe G, Giusti B, Attanasio M, Comeglio P, Porciani M, Giurlani L . A major involvement of the cardiovascular system in patients affected by Marfan syndrome: novel mutations in fibrillin 1 gene. J Mol Cell Cardiol. 1997; 29(7):1877-84. DOI: 10.1006/jmcc.1997.0426. View